THE FUTURE OF CERVICAL SCREENING Earn 3 CPD Points online Biomarkers and HPV testing: The future of cervical screening Professor John O Leary Associate Professor and Director of Pathology Coombe Women and Infants Hospital Trinity College, Dublin This presentation was made possible by an unrestricted educational grant from Roche Diagnostic, which had no control over content. SEPTEMBER 2014 1
Earn 3 CPD points at www.denovomedica.com Click on Accredited Education Programmes/CPD 2 SEPTEMBER 2014
SEPTEMBER 2014 3
Earn 3 CPD points at www.denovomedica.com Click on Accredited Education Programmes/CPD 4 SEPTEMBER 2014
The HPV negative woman SEPTEMBER 2014 5
Earn 3 CPD points at www.denovomedica.com Click on Accredited Education Programmes/CPD 6 SEPTEMBER 2014
SEPTEMBER 2014 7
Earn 3 CPD points at www.denovomedica.com Click on Accredited Education Programmes/CPD 8 SEPTEMBER 2014
SEPTEMBER 2014 9
Earn 3 CPD points at www.denovomedica.com Click on Accredited Education Programmes/CPD 10 SEPTEMBER 2014
SEPTEMBER 2014 11
Earn 3 CPD points at www.denovomedica.com Click on Accredited Education Programmes/CPD 12 SEPTEMBER 2014
SEPTEMBER 2014 13
14 SEPTEMBER 2014 Biomarkers and HPV testing: The future of cervical screening
References 1. Rodriquez AC, Schiffman M, Herrero R et al. Longitudinal study of human Papillomavirus persistence and cervical intra-epithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010; 102(5): 315-324. 2. Schiffman M, Wentzensen N. From human papillomarirus to cervical cancer. Obstetrics and Gynaecol 2010; 116(1): 177-185. 3. Meijer CJ, Berkhof H, Heideman DA, et al. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009, 46(Suppl 3): S1-4. 4. Dillner J, Rebolj M, Birembaut P, Petry KU, et al. Long term predictive values of cytology and HPV testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754. 5. Wright TC Jr, Stoler MH, Behrens CM, et al. The ATHENA human Papillomavirus study: design, methods and baseline results. Am J Obstet Gynaecol 2012; 206(1): 46.e1-46.e11 6. Van Rosmalen J, de Kok IM, van Ballegooijen M. Cost effectiveness of cervical screening: cytology versus HPV DNA testing. BJOG 2012; 119(6): 699-709. 7. Dijkstra MG, Snijders PJ, Arbyn M, et al. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Onco 2014; 25(5): 927-35. 8. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97(14): 1072-1079. 9. Cox JT, Castkle PE, Behrens CM, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 2013; 208(3):184. e1-184.e11. 10. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012; 130(3): 602-610. 11. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of highgrade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-ink4a results: a prospective analysis of a nested sub study of the NTCC randomised controlled trial. Lancet Oncol 2013; 14(2): 168-76. 12. Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors with p16/ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105(20): 1550-1557. CPD How to earn CPD points: Visit www.denovomedica.com, click on Accredited Educational Programmes/CPD, click on registration, then answer the relevant questionnaire. Your CPD certificate will be e-mailed to you within a week. Disclaimer The views and opinions expressed in the article are those of the presenters and do not necessarily reflect those of the publisher or its sponsor. In all clinical instances, medical practitioners are referred to the product insert documentation as approved by relevant control authorities. Published by 70 Arlington Street, Everglen, Cape Town, 7550 Tel: (021) 976 0485 I info@denovomedica.com SEPTEMBER 2014 15